AlloVir reports FY2021 net loss $172M; cash $248.1M; three Phase 3 trials advancing

Kalaris Therapeutics, Inc.

2022-FY EPS reported -$2.74

Net loss $172.0M ($2.74/share) for 2021 vs. $69.8M in 2020; cash $248.1M at year-end.
Three Phase 3 registrational studies of posoleucel: HC, AdV treatment enrolling; multi-virus prevention expected 1H22.
R&D expenses $120.7M in 2021; 2022 operating expense guidance $130-145M (excl. stock comp).
ALVR106 Phase 1/2 for respiratory viruses initiated Dec 2021; ALVR107 preclinical for hepatitis B ongoing.
Initial data from posoleucel BK viremia POC study in kidney transplant expected 1H22.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.